Stay updated on Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    12 days ago
    Change Detected
    Summary
    The value 04 16 has been updated to 05 07 on the webpage, indicating a recent change in the study record related to a clinical trial for Disitamab Vedotin alone or with Pembrolizumab in Urothelial Cancer that expresses HER2, sponsored by Seagen Inc. The change reflects the last update posted on May 7, 2024.
    Difference
    0.7%
    Check dated 2024-05-07T15:40:14.000Z thumbnail image
  7. Check
    18 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:24:40.000Z thumbnail image

Stay in the know with updates to Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Disitamab Vedotin & Pembrolizumab in HER2+ Urothelial Cancer Clinical Trial page.